Up regulation of KAI1 gene expression and apoptosis effect of imatinib mesylate in gastric adenocarcinoma (AGS) cell line

Asian Pacific Journal of Tropical Disease

Volumn 6, Issue 2, 2016, Pages 120-125

  Shandiz, Seyed Ataollah Sadat ^a   Farasati, Soheila ^b   Saeedi, Banafshe ^b   Baghbani Arani, Fahimeh ^b   Asl, Elham Akbari ^c   Keshavarz Pakseresht, Behta ^b   Rahimi, Arian ^d   Assadi, Artin ^e   Noorbazargan, Hassan ^f   Hesari, Maryam Rahimpour ^g   Mirzaie, Amir ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Apoptosis; Gastric cancer; Imatinib mesylate; KAI1 gene; Metastasis

Indexed keywords

IMATINIB; PROTEIN BAX; PROTEIN BCL 2;

ADENOCARCINOMA CELL LINE; APOPTOSIS; ARTICLE; BAX GENE; BCL 2 GENE; CELL COUNT; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FLOW CYTOMETRY; GAPDH GENE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KAI1 GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; UPREGULATION;

EID: 84958653444     PISSN: 22221808     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2222-1808(15)60996-3     Document Type: Article

References (35)

1. Constance JE, Woessner DW, Matissek KJ, Mossalam M, Lim CS Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib. Mol Pharmacol 2012, 9:3318-3329.
2. Siegel R, Ma J, Zou Zh, Jemal A. Cancer statistics. CA Cancer J Clin 2014, 64:9-29.
3. Rasul A, Yu B, Yang LF, Ali M, Khan M, Ma T, et al. Induction of mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells by kuraridin and Nor-kuraridin isolated from Sophora flavescens. Asian Pac J cancer Prev 2011, 12:2499-2504.
4. Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, et al. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst 2013, 105:405-423.
5. Weigel MT, Dahmke L, Schem CH, Bauerschlag DO, Weber K, Niehoff P, et al. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer 2010, 10:412.
6. Blay JY, Rutkowski P Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treat Rev 2014, 40:242-247.
7. Bansa S Is imatinib still the best choice as first-line oral TKI. South Asian J Cancer 2014, 3:83-86.
8. Rosenberg A, Mathew P Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. Expert Opin Investig Drugs 2013, 22:787-794.
9. Sadat Shandiz SA, Khosravani M, Mohammadi S, Noorbazargan H, Mirzaie A, Nouri Inanlou D, et al. Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-cells using quantitative real-time PCR. Asian Pac J Trop Biomed 2016, 2:159-163.
10. Davis H, Raja E, Miyazono K, Tsubakihara Y, Moustakas A Mechanisms of action of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev 2015, 10.1016/j.cytogfr.2015.11.009.
11. Jee BK, Lee JY, Lim Y, Lee KH, Jo YH Effect of KAI1/CD82 on the beta1 integrin maturation in highly migratory carcinoma cells. Biochem Biophys Res Commun 2007, 359:703-708.
12. Bozdogan O, Yulug G Vargel I, Cavusoglu T, Karabulut A, Karahan G, et al. Differential expression pattern of metastasis suppressor proteins in basal cell carcinoma. Int J Dermatol 2015, 54:905-915.
13. Haeno H, Michor F The evolution of tumor metastases during clonal expansion. J Theor Biol 2010, 263:30-44.
14. Liu FS, Dong JT, Chen JT, Hsieh YT, Ho ES, Hung MJ, et al. KAI1 metastasis suppressor protein is down regulated during the progression of human endometrial cancer. Clin Cancer Res 2003, 9:1393-1398.
15. Raggatt LJ, Partridge NC Cellular and molecular mechanisms of bone remodeling. J Biol Chem 2010, 285:25103-25108.
16. Patel BB, He YA, Li XM, Frolov A, Vanderveer L, Slater C, et al. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics 2008, 5:137-149.
17. Sadat Shandiz SA, Shafiee Ardestani M, Irani SH, Shahbazzadeh D Imatinib induces down regulation of Bcl-an anti-apoptotic protein in prostate cancer PC-cell line. Adv Stud Biol 2015, 7:17-27.
18. SaadZaghloul MA, Abadi AH, Abdelaziz AI Functional evaluation of imatinib mesylate in hepatocellular carcinoma cells. Recent Pat Biomark 2013, 7:65-71.
19. Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res 2011, 17:3924-3932.
20. Neuhouser ML Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer 2004, 50:1-7.
21. Sun W, Yang J Functional mechanisms for human tumor suppressors. J Cancer 2010, 1:136-140.
22. Waning D, Guise TA Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res 2014, 20:3071-3077.
23. Hinoda Y, Adachi Y, Takaoka A, Mitsuuchi H, Satoh Y, Itoh F, et al. Decreased expression of the metastasis suppressor gene KAI1 in gastric cancer. Cancer Lett 1998, 2:229-234.
24. Tang Y, Bhandaru M, Cheng Y, Lu J, Li G, Ong CJ The role of the metastasis suppressor gene KAI1 in melanoma angiogenesis. Pigment Cell Melanoma Res 2015, 28(6):696-706.
25. Zhang XA, He B, Zhou B, Liu L Requirement of the p130 CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem 2003, 278:27319-27328.
26. Zeviar DD, Gonzalez MJ, Miranda Massari JR, Duconge J, Mikirova N The role of mitochondria in cancer and other chronic diseases. J Orthomol Med 2014, 29:157-166.
27. He J, Xu H, Yang Y, Zhang X, Li XM Neuroprotective effects of olanzapine on methamphetamine induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl2 decrease in rats. Brain Res 2004, 1018:186-192.
28. Kinoshita K, Nakagawa K, Hamada J, Hida Y, Tada M, Kondo S, et al. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. Int J Oncol 2010, 37:869-877.
29. Groot JWB, Menacho IP, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JTM, et al. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 2006, 139:806-814.
30. Ross DM, Hughes TP Cancer treatment with kinase inhibitors: what have we learnt from imatinib?. Br J Cancer 2004, 90:12-19.
31. Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, Pages G, et al. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl positive K562 cell line and its differentiation towards the erythroid lineage. FASEB J 2003, 17:2160-2162.
32. Fernandes BF, Di Cesare S, Neto Belfort R, Maloney S, Martins C, Castiglione E, et al. Imatinib mesylate alters the expression of genes related to disease progression in an animal model of uveal melanoma. Anal Cell Pathol 2011, 34:123-130.
33. Kim JL, Kim BR, Na YJ, Park SH, Jeong YA, Oh SC Effect of imatinib mesylate in gastric cancer cell progression. Cancer Res 2015, 75(Suppl 15):3805-3815.
34. Odintsova E, van Niel G, Conjeaud H, Raposo G, Iwamoto R, Mekada E, et al. Metastsis suppressor tetraspanin CD82/KAI1 regulates ubiquitylation of epidermal growth factor receptor. J Boil Chem 2013, 288:26323-26334.
35. Riedy MC, Muiread KA, Jensen CP, Stewart CC Use of photolabeling technique to identify nonviable cells in fixed homologous or heterologous populations. Cytometry 1991, 12:133-139.